Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Withdraws Prexige In Australia Ahead Of FDA Decision Due To Deaths

This article was originally published in PharmAsia News

Executive Summary

A decision to withdraw Novartis' Prexige (lumiracoxib) in Australia after two patients died from serious liver injury following treatment with the drug is likely to impact the outcome of FDA's decision on a pending NDA for the COX-2 inhibitor

You may also be interested in...



Prexige Review Will Not Include FDA Arthritis Drugs Advisory Committee

Novartis expects action later this year on lumiracoxib after resubmitting the application, the company tells “The Pink Sheet” DAILY.

FDA Cold-Cox Merck; Arcoxia “Not Approvable” For Osteoarthritis

Agency indicates more data is needed on benefit-to-risk profile of the COX-2 inhibitor, but Merck is mum on whether it will continue to pursue approval.

Novartis Bullish About Prexige; Anticipates Blockbuster Potential

Company takes a more bullish stance on its COX-2 inhibitor than Merck, which has assumed FDA approval of its Vioxx follow-on product Arcoxia in 2007.

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel